Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure

Circulation

Volumn 100, Issue 3, 1999, Pages 268-273

  Davie, Andrew P ^a   Dargie, Henry J ^a   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin; Bradykinin; Heart failure; Vasodilation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; LOSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FOREARM BLOOD FLOW; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0033587529     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.3.268     Document Type: Article

References (33)

1. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta. 1970;214:374-376.
2. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med. 1974;291:817-821.
3. Solomon TA, Buckley JP. Inhibitory effects of central hypertensive activity of angiotensin I and II by 1-sar-8-ala-angiotensin 11 (saralasin acetate). J Pharm Sci. 1974;63:1109-1113.
4. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ14225 in man. N Engl J Med. 1978;298:991-995.
5. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PB. Nonpeptide angiotensin II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:711-718.
6. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC. Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan on the Elderly Study, ELITE). Lancet. 1997;349:747-752.
7. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. HOE 140, a new potent and long acting bradykinin antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
8. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. HOE 140, a new potent and long acting bradykinin antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
9. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
10. Regoli D, Rhaleb N-E, Dion S, Drapeau G. New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci. 1990;11:156-161.
11. Whitney RJ. The measurement of volume changes in human limbs. J Physiol. 1953;121:1-27.
12. Hokanson DE, Sumner DS, Strandness DE. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng. 1975;22:25-29.
13. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
14. Petrie JR, Ueda S, Morris AD, Murray LS, Elliott HL, Connell JMC. How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol. 1998;25:131-139.
15. Fox RH, Goldsmith R, Kidd DJ, Lewis GP. Bradykinin as a vasodilator in man. J Physiol. 1961;157:589-602.
16. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-1738.
17. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22: 579-584.
18. Cheng C-P. Onishi K, Ohte N, Suzuki M, Little WC. Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol. 1998;31:1679-1686.
19. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989;412:543-555.
20. Sharpe DN, Douglas JE, Coxon RJ, Long B. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet. 1980;316:1154-1157.
21. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-573.
22. Drexler H. Banhardt U, Meinertz T, Wollschlager H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation. 1989;79:491-502.
23. Yasujima M, Matthews PG, Johnston CI. Regulation of uterine smooth muscle bradykinin receptors by bradykinin levels and angiotensin converting enzyme inhibitor in the rat. Clin Exp Pharmacol Physiol. 1981; 8:515-518.
24. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effect of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
25. Cockcroft JR, Chowienczyk PJ, Brett SE, Bender N, Ritter JM. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol. 1994; 38:317-322.
26. Johnston CI, Millar JA, McGrath BP, Matthews PG. Long-term effects of captopril (SQ 14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979;314:493-496.
27. Johnston CI, Clappison BH, Anderson WP, Yasujima M. Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol. 1982;49:1401-1404.
28. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
29. Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local forearm vasodilation with intra-arterial administration of enalaprilat in humans. Clin Pharmacol Ther. 1991;50:314-321.
30. Newby DE, Masumori S, Johnston NR, Boon NA, Webb DJ. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. Cardiovasc Res. 1997; 36:268-275.
31. Faxon DP, Creager MA, Halperin JL. Regional circulatory response to converting-enzyme inhibition in congestive heart failure. Br J Clin Pharmacol. 1982;14:179S-186S.
32. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20: 1549-1555.
33. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, Poole-Wilson PA, Prentice CRM, Sutton GC. Is aspirin safe for patients with heart failure? Br Heart J. 1995;74:215-219.